<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel rdf:about="https://www.um.edu.mt/library/oar/handle/123456789/63305">
    <title>OAR@UM Collection:</title>
    <link>https://www.um.edu.mt/library/oar/handle/123456789/63305</link>
    <description />
    <items>
      <rdf:Seq>
        <rdf:li rdf:resource="https://www.um.edu.mt/library/oar/handle/123456789/34000" />
      </rdf:Seq>
    </items>
    <dc:date>2026-04-24T05:52:15Z</dc:date>
  </channel>
  <item rdf:about="https://www.um.edu.mt/library/oar/handle/123456789/34000">
    <title>Serum amyloid A in chronic obstructive pulmonary disease</title>
    <link>https://www.um.edu.mt/library/oar/handle/123456789/34000</link>
    <description>Title: Serum amyloid A in chronic obstructive pulmonary disease
Abstract: Introduction&#xD;
The Serum Amyloid A (SAA) protein family consists of differentially expressed&#xD;
apolipoproteins. There are four SAA genes responsible for encoding SAA in humans. SAA1&#xD;
and SAA2 encode the acute phase SAA (A-SAA) which may increase by 1000 fold following&#xD;
an acute phase response (APR). SAA3 is a pseudogene and SAA4 encodes constitutive SAA&#xD;
(C-SAA) which is not augmented following an APR. Studies have shown SAA proteins to be&#xD;
biomarkers of disease activity as well contributors to the development and progression of&#xD;
disease. Production is primarily hepatic, while localised expression has been detected at&#xD;
sites of inflammation including the lungs. In patients with chronic obstructive pulmonary&#xD;
disease (COPO), serum A-SAA levels are higher than in healthy individuals, and rise further&#xD;
following an acute exacerbation of COPO (AECOPO). Inflammatory cells, cytokines as well as&#xD;
SAA are elevated in the lungs and the levels may reflect the severity of COPO and the&#xD;
predicted mortality. Smoking cessation, as well as current pharmacological regimes are not&#xD;
effective enough at reducing the lung inflammation in COPO, and therefore further&#xD;
understanding of the cytokine-mediated expression of SAA, might contribute towards the&#xD;
potential identification of novel therapeutic targets.&#xD;
&#xD;
Aims&#xD;
This project aimed to study the cytokine-induced SAA transcriptional regulation in human&#xD;
airway-related cell line models. More specifically, it aimed to study the response of the&#xD;
SAA2 promoter to different concentrations of interleukin -1β (IL-β), interleukin-6 (IL-6),&#xD;
leukaemia inhibitory factor (LlF) and interleukin-8 (IL-8) in the alveolar epithelial A549 cell&#xD;
line and the monocytic-like human histiocytic lymphoma U937 cells. It also aimed to&#xD;
investigate temporal changes in serum SAA levels in stable COPO patients undergoing a 12-&#xD;
week pulmonary rehabilitation programme (PRP).&#xD;
&#xD;
Methodology&#xD;
The cytokine-mediated activity of the SAA2 promoter in airway-related cells was&#xD;
investigated using reporter gene assays. A pGL4.1O-SAA2 luciferase reporter construct, was&#xD;
transfected into AS49 pulmonary epithelial cells and U937 monocytic cells using FuGENE®&#xD;
HD transfection reagent. HepG2 cells were also transfected as a positive control. Following&#xD;
24 hours the cells were stimulated with different concentrations of IL-1β, IL-6, L1F and IL-&#xD;
8. Six and 24 hours post-stimulation, SAA2 promoter activity was quantified using dual&#xD;
luciferase reporter assays.&#xD;
Stable (OPD patients from Mater Dei Hospital out patients' clinic, who were undergoing a&#xD;
PRP, as part of a separate research project, were recruited for SAA analysis. This programme&#xD;
was of 12-week duration, covering twice-weekly classes of 2 hours, including 1 hour of&#xD;
exercise and 1 hour of education. Respiratory parameters and blood samples were taken at&#xD;
week 0, week 8 and week 12. Serum SAA concentrations at these time-points were analysed&#xD;
using ELlSA.&#xD;
Results&#xD;
The SAA2 promoter has been shown to be cytokine-inducible in all cell lines used.&#xD;
Transcriptional upregulation of the SAA2 promoter in HepG2 cells (control) occurred with all&#xD;
cytokines. IL-1β induced the highest SAA2 transcriptional regulatory activity at 24 hours in&#xD;
U937 (27.8 fold over unstimulated cells) and HepG2 (10.1 fold) cells, at concentrations of&#xD;
1.2ng/ml and 2ng/ml respectively. IL-8 at 40ng/ml induced a 5.7 fold increase in activity in&#xD;
U937 cells at 6 hours, while II 2.8 fold incrCu5C in SAA2 transcriptional activity was observed&#xD;
in AS49 with 20ng/ml of IL-8 at 24 hours. UF was only active in A549 cells, with maximal SAA&#xD;
promoter activity (3.0 fold) being observed at 40ng/ml of UF. IL-6 and L1F were ineffective in&#xD;
U937 cells.&#xD;
The median SAA concentration in stable (OPD patients was 38.1~g/ml with an interquartile&#xD;
range (IQR) of 52.0µg/ml at baseline, 61.6µg/ml (IQR of 85.4µg/ml) after 8 weeks (p&lt;0.05&#xD;
compared to baseline), and 41.4µg/ml (IQR of 74.3µg/ml) at week 12.&#xD;
&#xD;
&#xD;
Conclusion&#xD;
Inflammatory microenvironments can induce SAA2 transcription in airway-related cells, with&#xD;
the promoter being most active in IL-β-stimulated monocytes. This may have potential&#xD;
implications in understanding the interrelationships between these components of the pro-inflammatory&#xD;
network, and interpretation of their levels as clinical biomarkers.&#xD;
The observed PRP-related serum SAA level changes in COPD patients require further study&#xD;
in order to better understand the underlying mechanisms.
Description: M.SC. BIOMEDICAL SCI.</description>
    <dc:date>2015-01-01T00:00:00Z</dc:date>
  </item>
</rdf:RDF>

